Cancer BiologybioRxivPreprint
SS18-SSX co-opts P300 to sustain oncogenic transcription independent of SWI/SNF activity
Anthony M. Doherty, Eimear Lagan, Richard J. R. Elliott…·Gerard L. Brien
This study shows SS18-SSX sustains oncogenic transcription without needing SWI/SNF activity, identifies P300 as a critical co-factor, and demonstrates targeting P300 or SWI/SNF as therapeutic strategies.
1 citation